...
首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >New ePTFE/FEP-covered Stent in the Palliative Treatment of Malignant Biliary Obstruction.
【24h】

New ePTFE/FEP-covered Stent in the Palliative Treatment of Malignant Biliary Obstruction.

机译:新型ePTFE / FEP覆盖的支架用于姑息治疗恶性胆道梗阻。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To determine the technical efficacy and safety of an expanded polytetrafluoroethylene and fluorinated ethylene propylene (ePTFE/FEP)-covered metallic stent in the management of malignant biliary obstruction and to evaluate its clinical efficacy by estimating stent patency and patient survival rates. MATERIALS AND METHODS: Twenty-six patients with common bile duct stricture caused by malignant disease were treated by placement of 29 stents. The stent consists of an inner ePTFE/FEP lining and an outer supporting structure of nitinol wire. Multiple wire sections elevated from the external surface provide anchoring. Stents are available in two versions, with or without holes in the proximal stent lining. Holes should provide drainage of the cystic duct or biliary side branches when covered by the proximal stent end. Clinical evaluation and assessment of serum bilirubin and liver enzyme levels were done before stent placement and at 1, 3, 6, and 9 months. Average follow-up duration was 5.4 months (range, 5 d to 12.5 mo). RESULTS: Placement was successful in all cases. The 30-day mortality rate was 11.5%. The survival rates were 40% and 15% at 6 and 12 months, respectively. Eighty-four percent of patients had adequate palliative drainage during their lifetime. The stent patency rates were 91%, 77%, and 77% at 3, 6, and 12 months, respectively. Four patients (16%) presented with stent occlusion and needed repeat intervention. No migration occurred. Complications other than stent occlusion occurred in five patients (19%); among these, acute cholecystitis was observed in three patients (12%). CONCLUSION: Preliminary results suggest that placement of this ePTFE/FEP-covered stent is feasible and effective in achieving biliary drainage. The percentage of patients undergoing lifetime palliation and the midterm patency are promising. However, the incidence of acute cholecystitis is high. Treatment of a larger group of patients is mandatory to validate these long-term results.
机译:目的:确定扩大的聚四氟乙烯和氟化乙烯丙烯(ePTFE / FEP)覆盖的金属支架在治疗恶性胆道梗阻中的技术疗效和安全性,并通过评估支架通畅性和患者生存率来评估其临床疗效。材料与方法:26例因恶性疾病而引起的胆总管狭窄的患者,通过置入29个支架进行治疗。支架由内部ePTFE / FEP衬里和镍钛诺线的外部支撑结构组成。从外表面抬起的多个线段可提供锚固作用。支架有两种版本,近侧支架衬里有无孔。当孔被支架的近端覆盖时,孔应为胆囊管或胆道侧支提供引流。在支架置入前,1、3、6和9个月进行了血清胆红素和肝酶水平的临床评估和评估。平均随访时间为5.4个月(范围为5 d至12.5 mo)。结果:在所有情况下都可以成功放置。 30天死亡率为11.5%。 6个月和12个月的生存率分别为40%和15%。 84%的患者一生中有足够的姑息引流。在3、6和12个月时,支架的通畅率分别为91%,77%和77%。四名患者(16%)表现为支架阻塞,需要再次干预。没有发生迁移。 5例患者发生了除支架闭塞以外的并发症(19%)。其中,三名患者(12%)观察到急性胆囊炎。结论:初步结果表明,这种ePTFE / FEP覆盖支架的放置对于实现胆道引流是可行和有效的。终生缓解和中期通畅的患者百分比很有希望。但是,急性胆囊炎的发生率很高。为了验证这些长期结果,必须对大量患者进行治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号